Literature DB >> 18194821

Effect of chronic beta-blockade on QT interval in patients with liver cirrhosis.

Andrea Zambruni1, Franco Trevisani, Antonio Di Micoli, Francesco Savelli, Annalisa Berzigotti, Eleonora Bracci, Paolo Caraceni, Marco Domenicali, Palmiro Felline, Marco Zoli, Mauro Bernardi.   

Abstract

BACKGROUND/AIMS: QT interval prolongation is frequent in cirrhosis, predicts a poor prognosis and may trigger severe ventricular arrhythmias. Our aim was to evaluate the effect of chronic beta-blockade on QT prolongation.
METHODS: Clinical and laboratory evaluation, ECG and hepatic vein pressure gradient (HVPG) measurement were performed in 30 cirrhotic patients before and 1-3 months after prophylactic nadolol. QT was corrected for heart rate by the cirrhosis-specific formula and other formulas.
RESULTS: QT(cirrhosis) was prolonged in 10 patients (33%); HVPG was increased in all cases. QT(cirrhosis) was correlated with the Child-Pugh score (r=0.40; p=0.027). Nadolol shortened QT interval only with the Bazett formula (p=0.01), remaining unchanged with the other formulas. The QT interval shortened only if prolonged at baseline (from 473.3+/-5.5 to 458.4+/-6.5 ms; p=0.007), while it lengthened when normal (from 429.8+/-3.1 to 439.3+/-2.9 ms; p=0.01). QTc changes were directly related to the baseline value (p<0.001). HVPG decreased from 19.4+/-0.8 to 15.6+/-1.3 mmHg (p=0.004). The HVPG changes did not correlate with QTc changes.
CONCLUSIONS: Chronic beta-blockade shortens the QT interval only in patients with prolonged baseline values, and this is likely due to a direct cardiac effect.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18194821     DOI: 10.1016/j.jhep.2007.11.012

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  21 in total

Review 1.  Drug-induced QT interval shortening: potential harbinger of proarrhythmia and regulatory perspectives.

Authors:  Rashmi R Shah
Journal:  Br J Pharmacol       Date:  2009-06-25       Impact factor: 8.739

2.  QT interval prolongation in end-stage liver disease cannot be explained by nonhepatic factors.

Authors:  Divyang Patel; Prabhpreet Singh; William Katz; Christopher Hughes; Kapil Chopra; Jan Němec
Journal:  Ann Noninvasive Electrocardiol       Date:  2014-04-24       Impact factor: 1.468

Review 3.  Cirrhotic cardiomyopathy: Implications for the perioperative management of liver transplant patients.

Authors:  Suehana Rahman; Susan V Mallett
Journal:  World J Hepatol       Date:  2015-03-27

Review 4.  Modulation of the QT interval duration in hypertension with antihypertensive treatment.

Authors:  Jan Klimas; Peter Kruzliak; Simon W Rabkin
Journal:  Hypertens Res       Date:  2015-03-19       Impact factor: 3.872

5.  Cirrhotic cardiomyopathy.

Authors:  Florence Wong
Journal:  Hepatol Int       Date:  2008-11-11       Impact factor: 6.047

6.  Free Cortisol Is a More Accurate Marker for Adrenal Function and Does Not Correlate with Renal Function in Cirrhosis.

Authors:  Eleni Theocharidou; Olga Giouleme; Sotirios Anastasiadis; Aikaterini Markopoulou; Efstathios Pagourelias; Themistoklis Vassiliadis; Athanasios Fotoglidis; Polyxeni Agorastou; Aristeidis Slavakis; Aikaterini Balaska; Maria G Kouskoura; Thomas D Gossios; Asterios Karagiannis; Christos S Mantzoros
Journal:  Dig Dis Sci       Date:  2019-01-19       Impact factor: 3.199

7.  Cirrhotic cardiomyopathy: Isn't stress evaluation always required for the diagnosis?

Authors:  Mara Barbosa; Joana Guardado; Carla Marinho; Bruno Rosa; Isabel Quelhas; António Lourenço; José Cotter
Journal:  World J Hepatol       Date:  2016-01-28

Review 8.  Cirrhotic cardiomyopathy.

Authors:  Luis Ruiz-del-Árbol; Regina Serradilla
Journal:  World J Gastroenterol       Date:  2015-11-07       Impact factor: 5.742

9.  Diagnosis and Management of Cirrhotic Cardiomyopathy.

Authors:  Harpreet Kaur; Madhumita Premkumar
Journal:  J Clin Exp Hepatol       Date:  2021-08-21

10.  The end-organ impairment in liver cirrhosis: appointments for critical care.

Authors:  Antonio Figueiredo; Francisco Romero-Bermejo; Rui Perdigoto; Paulo Marcelino
Journal:  Crit Care Res Pract       Date:  2012-05-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.